DUBLIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and
development of novel cancer therapies, today presented data on MP-470, its
lead product candidate, and four additional posters, at the 20th
EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in
Geneva, Switzerland. MP-470, an orally bio-available multi-targeted
tyrosine kinase inhibitor, showed encouraging tumor regression results in
the first two arms (paclitaxel/carboplatin and carboplatin/etoposide) of
its current Phase 1b clinical trial examining MP-470 combined with five
standard of care (SOC) anticancer treatments.

"We are extremely pleased to report a series of important clinical and
scientific advances achieved by our Company," said James S. Manuso, Ph.D.,
SuperGen's President and Chief Executive Officer. "In addition to MP-470's
progress in the clinic, before year-end, we expect to enter SGI-1776, our
PIM kinase inhibitor, into Phase 1 clinical trials. This will be our second
novel drug in clinical development."

In a poster presentation (Abstract #403) entitled, "Clinical responses
of highly refractory solid tumor patients to oral MP-470, a multi-targeted
tyrosine kinase inhibitor, in combination with standard of care
chemotherapy regimens. Preliminary report from a multi-institutional phase
1b clinical trial," Dr. A. Tolcher, Director of Clinical Research at START
(South Texas Accelerated Research Therapeutics) in San Antonio, Texas,
highlighted data showing tumor regression in four patients in the two arms,
indicating that MP-470 may sensitize/re-sensitize tumors to the anticancer
effects of SOC regimens of DNA-damaging agents. Of note, MP-470 did not
increase the types or severity of adverse events. However, a primary
endpoint of the trial - determining the maximum tolerated dose of MP-470
co-administered with SOC regimens - has not been reached and dose
escalation continues.

"These compelling results strengthen the rationale for combining MP-470
with DNA-damaging agents due to MP-470's purported ability to suppress the
Rad51 DNA repair mechanism, which is important in various malignancies,"
said Dr. Gregory Berk, SuperGen's Chief Medical Officer. "We look forward
to presenting updated results on MP-470 in combination with these platinum
doublets, as well as the other three standard of care arms of the trial in
the future."

Earlier this year, U.S. Food and Drug Administration granted orphan
drug designation for MP-470 in the treatment of glioblastoma multiforme
(GBM) after non-clinical studies showed more than two-fold effect of
increased cell death when used synergistically with ionizing radiation.
Orphan drug designation for GBM, an often fatal form of brain cancer, can
entitle SuperGen to seven years of market exclusivity. SuperGen's lead
product candidate has also shown promise in preclinical testing across a
wide spectrum of cancers, including non-small cell lung cancer.

Furthermore, SuperGen presented four additional posters at the
Symposium that reviewed clinical and non-clinical advances of the compounds
MP-470, SGI-1776 and SGI-1252. These include:

Abstract 571: Modulation of JAK2 signaling pathways in vitro and in vivo

Copies of the 20th EORTC-NCI-AACR Symposium poster presentations will
be available in the pipeline section of SuperGen's Web site
http://www.supergen.com.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company
dedicated to the discovery and development of novel cancer therapies.
SuperGen is developing a number of therapeutic anticancer products focused
on kinase and cell signaling inhibitors and DNA methyltransferase
inhibitors. For more information about SuperGen, please visit
http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects,"
"anticipate," "intends," "will," "may," "should," or similar expressions.
These forward-looking statements are not guarantees of future performance
and involve a number of risks and uncertainties that may cause actual
results to differ materially from the results discussed in these
statements. Factors that might cause the company's results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, the ability to discover,
develop and move target compounds into clinical development and other risks
and uncertainties detailed from time to time in the company's filings with
the Securities and Exchange Commission including its most recently filed
Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of
these forward-looking statements to conform them to actual results.

(Date:10/12/2017)... ... 12, 2017 , ... They call it the “hairy ball.” ... depiction of a system of linkages and connections so complex and dense that ... computer science at Worcester Polytechnic Institute (WPI) and director of the university’s bioinformatics ...

(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...

(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...

(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...

(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...

(Date:5/23/2017)... Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...

(Date:5/16/2017)... , May 16, 2017 Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...